Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of berzatinib + PLB1004 versus platinum doublet chemotherapy in EGFR-mutant, MET-amplified/overexpressing advanced non-squamous NSCLC after EGFR-TKI failure
CTR20251719Phase 3Active
- Sponsor
- Anshi Pharma
- Start
- May 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vebreltinib, andamertinib in non-small cell lung cancer (NSCLC), sponsored by Anshi Pharma. Started May 2025; status: active.
02
Drugs
vebreltinibandamertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20251719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251719.